Expression Of Vascular Endothelial Growth Factor And Its Soluble Receptor1in Ovarian Tissues And Serum Of Polycystic Ovary Syndrome

Objective: To investigate the expression of vascular endothelialgrowth factor and its soluble receptor1in ovarian tissues and serum ofpolycystic ovary syndrome and control group.Methods: Enzyme linked immunosorbent assay was used toinvestigate the expression of VEGF and sFlt-1of46PCOS patients(experimental group) and25normal patients (control group) in serum. Thelevels of VEGF and sFlt-1in ovarian tissues were detected by Spimmunohistochemical method (including9PCOS cases and7control cases).Results:1. In serum, VEGF and sFlt-1concentrations were49.18pg/mland49.25ng/L in PCOS group, and were34.45pg/ml and389.37ng/L in thecontrol group. There were significant differences in the two groups (P<0.05).2. In ovarian tissue, VEGF and sFlt-1expression were0.24±0.03and0.17±0.04in PCOS group, and were0.18±0.02and0.26±0.05in controlgroup, the differences were statistically significant (P <0.05).3. In serum andovarian tissue, VEGF bioavailability (VEGF/sFlt-1) were higher, the differences were statistically significant.4. Research in serum VEGF andsFlt-1correlation, there was negative correlation（rs=-0.435,P＜0.05）.Conclusion:1.In serum and ovarian tissue expression of VEGF is increasedwhich may promote ovarian local blood vessel formation.2. In serum andovarian tissue expression of sFlt-1is decreased the which may negativelyregulate VEGF expression or be a direct role in the ovarian tissue, toparticipate in PCOS ovarian blood vessel formation.3. VEGF and sFlt-1may influence the occurrence and development of PCOS.